apexxnar
pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 8, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 10a, pneumococcal polysaccharide serotype 11a, pneumococcal polysaccharide serotype 12f, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 15b, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 22f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 33f - ΠΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΎΠ²ΠΈ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ - ΠΠ°ΠΊΡΠΈΠ½ΠΈ - active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. ΠΠΈΠΆΡΠ΅ ΡΠ°Π·Π΄Π΅Π»ΠΈ 4. 4 ΠΈ 5. 1 Π·Π° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎΡΠ½ΠΎΡΠ½ΠΎ Π·Π°ΡΠΈΡΠ°ΡΠ° ΡΡΠ΅ΡΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΎΠ²ΠΈ ΡΠ΅ΡΠΎΡΠΈΠΏΠΎΠ²Π΅. apexxnar should be used in accordance with official recommendations. .
synflorix
glaxosmithkline biologicals s.a. - pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19f - pneumococcal infections; immunization - ΠΠ°ΠΊΡΠΈΠ½ΠΈ - ΠΠΊΡΠΈΠ²Π½Π° ΠΈΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΡ ΡΡΠ΅ΡΡ ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΎ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½Π΅ ΠΈ ΠΎΡΡΡΡ ΠΎΡΠΈΡ Π½Π° ΡΡΠ΅Π΄Π½ΠΎΡΠΎ ΡΡ ΠΎ, ΠΏΡΠΈΡΠΈΠ½Π΅Π½ΠΈ ΠΎΡ streptococcus pneumoniae ΠΏΡΠΈ Π±Π΅Π±Π΅ΡΠ° ΠΈ Π΄Π΅ΡΠ° ΠΎΡ ΡΠ΅ΡΡ ΡΠ΅Π΄ΠΌΠΈΡΠΈ Π½Π°Π³ΠΎΡΠ΅ Π΄ΠΎ ΠΏΠ΅Ρ Π³ΠΎΠ΄ΠΈΠ½ΠΈ Π½Π° Π²ΡΠ·ΡΠ°ΡΡ. ΠΠΈΠΆΡΠ΅ ΡΠ°Π·Π΄Π΅Π»ΠΈ 4. 4 ΠΈ 5. 1 Π² ΠΏΡΠΎΠ΄ΡΠΊΡΠΎΠ²Π°ΡΠ° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ Π·Π° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ Π·Π° Π·Π°ΡΠΈΡΠ° ΡΡΠ΅ΡΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΎΠ²ΠΈ ΡΠ΅ΡΠΎΡΠΈΠΏΠΎΠ²Π΅. ΠΡΠΈΠ»Π°Π³Π°Π½Π΅ΡΠΎ Π½Π° Π²Π°ΠΊΡΠΈΠ½Π°ΡΠ° synflorix ΡΡΡΠ±Π²Π° Π΄Π° ΡΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Ρ Π²ΡΠ· ΠΎΡΠ½ΠΎΠ²Π° Π½Π° ΠΎΡΠΈΡΠΈΠ°Π»Π½ΠΈ ΠΏΡΠ΅ΠΏΠΎΡΡΠΊΠΈ, ΠΊΠ°ΡΠΎ ΡΠ΅ Π²Π·Π΅ΠΌΠ΅ ΠΏΡΠ΅Π΄Π²ΠΈΠ΄ Π²Π»ΠΈΡΠ½ΠΈΠ΅ΡΠΎ Π½Π° ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ Π² ΡΠ°Π·Π»ΠΈΡΠ½ΠΈΡΠ΅ Π²ΡΠ·ΡΠ°ΡΡΠΎΠ²ΠΈ Π³ΡΡΠΏΠΈ, ΠΊΠ°ΠΊΡΠΎ ΠΈ ΠΏΡΠΎΠΌΠ΅Π½Π»ΠΈΠ²ΠΎΡΡΡΠ° Π½Π° ΡΠ΅ΡΠΎΡΠΈΠΏ Π½Π° Π΅ΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡΡΠ° Π² ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ Π³Π΅ΠΎΠ³ΡΠ°ΡΡΠΊΠΈ ΡΠ°ΠΉΠΎΠ½ΠΈ.
prevenar 13
pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f - pneumococcal infections; immunization - ΠΠ°ΠΊΡΠΈΠ½ΠΈ - ΠΠΊΡΠΈΠ²Π½Π° ΠΈΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΡ Π·Π° ΠΏΡΠ΅Π΄ΠΎΡΠ²ΡΠ°ΡΡΠ²Π°Π½Π΅ Π½Π° ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ, ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΡ ΠΈ ΠΎΡΡΡΡ ΠΎΡΠΈΡ Π½Π° ΡΡΠ΅Π΄Π½ΠΎΡΠΎ ΡΡ ΠΎ, ΠΏΡΠΈΡΠΈΠ½Π΅Π½ΠΈ ΠΎΡ streptococcus pneumoniae ΠΏΡΠΈ Π±Π΅Π±Π΅ΡΠ°, Π΄Π΅ΡΠ° ΠΈ ΡΠ½ΠΎΡΠΈ ΠΎΡ 6 ΡΠ΅Π΄ΠΌΠΈΡΠΈ Π΄ΠΎ 17 Π³ΠΎΠ΄ΠΈΡΠ½Π° Π²ΡΠ·ΡΠ°ΡΡ. ΠΠΊΡΠΈΠ²Π½Π° ΠΈΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΡ Π·Π° ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° Π½Π° ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ, ΠΏΡΠΈΡΠΈΠ½Π΅Π½ΠΈ ΠΎΡ streptococcus pneumoniae ΠΏΡΠΈ Π²ΡΠ·ΡΠ°ΡΡΠ½ΠΈ β₯18 Π³ΠΎΠ΄ΠΈΠ½ΠΈ ΠΈ ΠΏΠΎ-Π²ΡΠ·ΡΠ°ΡΡΠ½ΠΈ Ρ ΠΎΡΠ°. ΠΠΈΠΆΡΠ΅ ΡΠ°Π·Π΄Π΅Π»ΠΈ 4. 4 ΠΈ 5. 1 Π·Π° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎΡΠ½ΠΎΡΠ½ΠΎ Π·Π°ΡΠΈΡΠ°ΡΠ° ΡΡΠ΅ΡΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΎΠ²ΠΈ ΡΠ΅ΡΠΎΡΠΈΠΏΠΎΠ²Π΅. ΠΠ·ΠΏΠΎΠ»Π·Π²Π°Π½Π΅ΡΠΎ Π½Π° ΠΡΠ΅Π²Π΅Π½Π°Ρ 13 ΡΡΡΠ±Π²Π° Π΄Π° ΡΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΠΈ Π²ΡΠ· ΠΎΡΠ½ΠΎΠ²Π° Π½Π° ΠΎΡΠΈΡΠΈΠ°Π»Π½ΠΈ ΠΏΡΠ΅ΠΏΠΎΡΡΠΊΠΈ, ΠΊΠ°ΡΠΎ ΡΠ΅ Π²Π·Π΅ΠΌΠ΅ ΠΏΡΠ΅Π΄Π²ΠΈΠ΄ ΡΠΈΡΠΊΡΡ ΠΎΡ ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ Π² ΡΠ°Π·Π»ΠΈΡΠ½ΠΈΡΠ΅ Π²ΡΠ·ΡΠ°ΡΡΠΎΠ²ΠΈ Π³ΡΡΠΏΠΈ, Π² ΠΎΡΠ½ΠΎΠ²Π°ΡΠ° Π½Π° ΡΡΠΏΡΡΡΡΠ²Π°ΡΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ, ΠΊΠ°ΠΊΡΠΎ ΠΈ Π²Π°ΡΠΈΠ°Π±Π΅Π»ΡΠ½ΠΎΡΡΡ ΡΠ΅ΡΠΎΡΠΈΠΏΠ° Π½Π° Π΅ΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡΡΠ° Π² ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ Π³Π΅ΠΎΠ³ΡΠ°ΡΡΠΊΠΈ ΡΠ°ΠΉΠΎΠ½ΠΈ.
prevenar
pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - ΠΠ°ΠΊΡΠΈΠ½ΠΈ - ΠΠΊΡΠΈΠ²Π½Π° ΠΈΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΡ ΡΡΠ΅ΡΡ Π±ΠΎΠ»Π΅ΡΡ, ΠΏΡΠΈΡΠΈΠ½Π΅Π½Π° ΠΎΡ streptococcus pneumoniae ΡΠ΅ΡΠΎΡΠΈΠΏΠΎΠ²Π΅ 4, 6b, 9v, 14, 18 c, 19Π΅ ΠΈ 23f (Π²ΠΊΠ»ΡΡΠΈΡΠ΅Π»Π½ΠΎ ΡΠ΅ΠΏΡΠΈΡ, ΠΌΠ΅Π½ΠΈΠ½Π³ΠΈΡ, ΠΏΠ½Π΅Π²ΠΌΠΎΠ½ΠΈΡ, Π±Π°ΠΊΡΠ΅ΡΠΈΠ΅ΠΌΠΈΡ ΠΈ ΠΎΡΡΡΡ ΠΎΡΠΈΡ) ΠΏΡΠΈ Π±Π΅Π±Π΅ΡΠ° ΠΈ Π΄Π΅ΡΠ° ΠΎΡ Π΄Π²Π° ΠΌΠ΅ΡΠ΅ΡΠ° Π΄ΠΎ ΠΏΠ΅Ρ Π³ΠΎΠ΄ΠΈΠ½ΠΈ Π½Π° Π²ΡΠ·ΡΠ°ΡΡ. ΠΠ·ΠΏΠΎΠ»Π·Π²Π°Π½Π΅ΡΠΎ Π½Π° ΠΡΠ΅Π²Π΅Π½Π°Ρ ΡΡΡΠ±Π²Π° Π΄Π° ΡΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Ρ Π²ΡΠ· ΠΎΡΠ½ΠΎΠ²Π° Π½Π° ΠΎΡΠΈΡΠΈΠ°Π»Π½ΠΈ ΠΏΡΠ΅ΠΏΠΎΡΡΠΊΠΈ, ΠΊΠ°ΡΠΎ ΡΠ΅ Π²Π·Π΅ΠΌΠ΅ ΠΏΡΠ΅Π΄Π²ΠΈΠ΄ Π²Π»ΠΈΡΠ½ΠΈΠ΅ΡΠΎ Π½Π° ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΠΈ Π·Π°Π±ΠΎΠ»ΡΠ²Π°Π½ΠΈΡ Π² ΡΠ°Π·Π»ΠΈΡΠ½ΠΈΡΠ΅ Π²ΡΠ·ΡΠ°ΡΡΠΎΠ²ΠΈ Π³ΡΡΠΏΠΈ, ΠΊΠ°ΠΊΡΠΎ ΠΈ ΠΏΡΠΎΠΌΠ΅Π½Π»ΠΈΠ²ΠΎΡΡΡΠ° Π½Π° ΡΠ΅ΡΠΎΡΠΈΠΏ Π½Π° Π΅ΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡΡΠ° Π² ΡΠ°Π·Π»ΠΈΡΠ½ΠΈ Π³Π΅ΠΎΠ³ΡΠ°ΡΡΠΊΠΈ ΡΠ°ΠΉΠΎΠ½ΠΈ.
vaxneuvance
merck sharp & dohme b.v.Β - pneumococcal polysaccharide conjugate vaccine (adsorbed) - ΠΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΎΠ²ΠΈ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. ΠΠΈΠΆΡΠ΅ ΡΠ°Π·Π΄Π΅Π»ΠΈ 4. 4 ΠΈ 5. 1 Π·Π° ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎΡΠ½ΠΎΡΠ½ΠΎ Π·Π°ΡΠΈΡΠ°ΡΠ° ΡΡΠ΅ΡΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΈ ΠΏΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΎΠ²ΠΈ ΡΠ΅ΡΠΎΡΠΈΠΏΠΎΠ²Π΅. the use of vaxneuvance should be in accordance with official recommendations.
pneumo 23 solution for injection 0,5 ml
sanofi pasteur s.a. - ΠΠ½Π΅Π²ΠΌΠΎΠΊΠΎΠΊΠΊΠΎΠ²Π°Ρ ΠΏΠΎΠ»ΠΈΡΠ°Ρ Π°ΡΠΈΠ΄Π½Π°Ρ Π²Π°ΠΊΡΠΈΠ½Π° - solution for injection 0,5 ml
flebogamma dif (previously flebogammadif)
instituto grifols s.a. - ΠΠΌΡΠ½ΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½ Π½ΠΎΡΠΌΠ°Π»Π΅Π½ ΡΠΎΠ²Π΅ΠΊ - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - ΠΠΌΡΠ½Π½ΠΈ ΡΠ΅ΡΡΠΌΠΈ ΠΈ ΠΈΠΌΡΠ½ΠΎΠ³Π»ΠΎΠ±ΡΠ»ΠΈΠ½ΠΈ - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barrΓ© syndrome;, kawasaki disease.
clindavet - bg tabs 150 mg
provet s. a. - ΠΠ° Π±Π°Π·Π°ΡΠ° Π½Π° ΠΊΠ»ΠΈΠ½Π΄Π°ΠΌΠΈΡΠΈΠ½ (ΠΏΠΎΠ΄ ΡΠΎΡΠΌΠ°ΡΠ° Π½Π° Ρ ΠΈΠ΄ΡΠΎΡ Π»ΠΎΡΠΈΠ΄) - ΡΠ°Π±Π»Π΅ΡΠΊΠΈ - 150 mg/ΡΠ°Π±Π»Π΅ΡΠΊΠ° - ΠΊΡΡΠ΅ΡΠ°
clindavet - bg tabs 75 mg
provet s. a. - ΠΠ° Π±Π°Π·Π°ΡΠ° Π½Π° ΠΊΠ»ΠΈΠ½Π΄Π°ΠΌΠΈΡΠΈΠ½ (ΠΏΠΎΠ΄ ΡΠΎΡΠΌΠ°ΡΠ° Π½Π° Ρ ΠΈΠ΄ΡΠΎΡ Π»ΠΎΡΠΈΠ΄) - ΡΠ°Π±Π»Π΅ΡΠΊΠΈ - 75 mg/ΡΠ°Π±Π»Π΅ΡΠΊΠ° - ΠΊΡΡΠ΅ΡΠ°
intertrim la
interchemie werken de adelaar b.v. - Π‘ΡΠ»ΡΡΠ°Π΄ΠΎΠΊΡΠΈΠ½, Π’ΡΠΈΠΌΠ΅ΡΠΎΠΏΡΠΈΠΌ - ΠΈΠ½ΠΆΠ΅ΠΊΡΠΈΠΎΠ½Π΅Π½ ΡΠ°Π·ΡΠ²ΠΎΡ - 200 mg/ml; 40 mg/ml - Π³ΠΎΠ²Π΅Π΄Π°, ΠΊΠΎΠ½Π΅, ΠΏΡΠ°ΡΠ΅ΡΠ°